Navigation Links
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target

any diabetes drug for an eight- week period. Patients were then randomized to receive one of four once-daily doses of liraglutide (0.1, 0.3, 0.6, and 0.9 mg) or placebo. Baseline A1c levels ranged between 8.1 to 8.5%. The randomized, 14-week study showed statistically significant dose-dependent reductions in A1c levels (ranging from 0.79 to 1.85 percentage points - placebo adjusted, p<0.0001) after once- daily dosing of liraglutide monotherapy in these patients. Further, A1c levels below 7 percent were achieved by 22, 43, 62 and 75 percent of patients receiving liraglutide 0.1, 0.3, 0.6 and 0.9 mg/day compared with 9 percent of those receiving placebo. Additionally, in these normal-weight subjects (average BMI 23.9) no relevant changes in body weight or major or minor hypoglycemic events occurred in any study group.(1)

The main gastrointestinal adverse events in the high dose group versus placebo were: constipation (7% versus 9%), diarrhea (9% versus 4%), gastritis (7% vs. 0%) and nausea (7% versus 2%). No subject had a treatment-related increase in liraglutide antibodies.

About liraglutide

Currently in phase 3 clinical trials, liraglutide is a human analog of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. GLP-1 is released from the gastrointestinal tract upon ingestion of food. When glucose levels become too high, GLP-1 triggers the release of insulin from the pancreas and decreases the secretion of glucagon, a hormone that promotes glucose synthesis in the liver. GLP-1 releases insulin in a glucose-dependent manner, meaning that it only triggers insulin secretion if blood glucose is too high. This characteristic is thought to result in a low risk of hypoglycemia, which has been confirmed in a number of studies in which GLP-1 was infused intravenously or subcutaneously.

Novo Nordisk is a healthcare company and a world lead
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/30/2014)... 2014 Arbor Pharmaceuticals, LLC. - Product ... Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product Pipeline ... Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Arbor Pharmaceuticals, LLC.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... Sept. 30, 2014  According to their CEO, ... cancer clinical trials is going through a complete ... the work of the current clinical trial management ... ,next generation, clinical trials, which will ultimately drive ... The company has been recognized by the ...
(Date:9/30/2014)... A study using a relatively new imaging ... at the composition of carotid artery disease and has ... the disease, a leading cause of stroke. ... September 2010 and May 2012, was featured in the ... American College of Cardiology (JACC) Cardiovascular Interventions. Interventional ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
(Date:9/30/2014)... been awarded a three-year $1.7 million grant from ... new imaging technologies and data analysis techniques that ... of neurons in the brain interact to process ... the precise interactions between millions of nerve cells ... alterations in these interactions that may be responsible ...
(Date:9/30/2014)... EverStryke , the permanent match currently offered by ... a free book and class all about survival education and ... investigative review. , “Joe Marshall of SurvivalLife.com is one ... niche, and this product is an excellent way to get ... that Joe offers on his website to help people be ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... plastic surgery providers in Turkey has gone up more ... of growth. The medical tourism company also reported total ... since October 2012. , The company’s professional strategy has ... in Turkey — ultimately designed for patient comfort and ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... Calif., July 1 Everock, Inc. (Pink Sheets: EVRN) announced ... privately held Nature,s Peak, Inc. whereby its business assets and ... Peak has assumed control of the newly combined company and, ... reflect this. Paul Wilkinson, founder and CEO of Nature,s Peak ...
... ... recognized by PRSA with a Bronze Anvil for its media relations efforts for Catholic Healthcare ... ... and new media agency, has been recognized by PRSA with a Bronze Anvil for its ...
... YORK, July 1 The Nielsen Company , ... one of the world,s most recognized international advertising and design competitions, ... is now accepting online entry submissions at www.CLIOHealthcare.com ... work appearing between January 1, 2008 and June 30, 2009. , ...
... fifth graders and their younger siblings, recently received $1.45 ... part of the National Institutes of Health,s American Recovery ... years. The program aims to enhance the quality ... behavior and use of drugs among youth as they ...
... Veterinarians for Dedication to Improving Animal Health and Well-Being ... veterinarian for the third annual Thank Your Vet for ... (MAF). The national short-essay contest honors America,s veterinarians for ... we have with our pets. The nationwide essay contest ...
... prevent disease, lower health care costs , , ... organizations in health care, science, medicine and public health ... goal in mind: to develop a national physical activity ... members of the public both agree that emphasizing disease ...
Cached Medicine News:Health News:Everock, Inc. Completes Reverse Merger with Privately Held All-Natural Food Producer, Nature's Peak 2Health News:Everock, Inc. Completes Reverse Merger with Privately Held All-Natural Food Producer, Nature's Peak 3Health News:Tempe-Based Marketing Agency Receives Prestigious National Healthcare Marketing Award, Several Regional Awards 2Health News:Tempe-Based Marketing Agency Receives Prestigious National Healthcare Marketing Award, Several Regional Awards 3Health News:Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries 2Health News:Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries 3Health News:Search for America's Best Veterinarian Continues With Third Annual 'Thank Your Vet for a Healthy Pet(R)' Contest 2Health News:Policymakers, Experts, Public Agree: Physical Activity Plan Needed 2Health News:Policymakers, Experts, Public Agree: Physical Activity Plan Needed 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: